- Home
- BCAX vs GAIN Comparison
BCAX vs GAIN Comparison
Compare BCAX & GAIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAX
- GAIN
- Stock Information
- Founded
- BCAX 2018
- GAIN 2005
- Country
- BCAX United States
- GAIN United States
- Employees
- BCAX N/A
- GAIN N/A
- Industry
- BCAX
- GAIN Finance: Consumer Services
- Sector
- BCAX
- GAIN Finance
- Exchange
- BCAX NYSE
- GAIN Nasdaq
- Market Cap
- BCAX 670.9M
- GAIN 550.0M
- IPO Year
- BCAX 2024
- GAIN 2005
- Fundamental
- Price
- BCAX $9.32
- GAIN $14.07
- Analyst Decision
- BCAX Strong Buy
- GAIN Hold
- Analyst Count
- BCAX 7
- GAIN 2
- Target Price
- BCAX $29.17
- GAIN $13.50
- AVG Volume (30 Days)
- BCAX 1.4M
- GAIN 194.5K
- Earning Date
- BCAX 08-16-2025
- GAIN 08-04-2025
- Dividend Yield
- BCAX N/A
- GAIN 10.66%
- EPS Growth
- BCAX N/A
- GAIN N/A
- EPS
- BCAX N/A
- GAIN 1.78
- Revenue
- BCAX N/A
- GAIN $93,662,000.00
- Revenue This Year
- BCAX N/A
- GAIN $6.09
- Revenue Next Year
- BCAX N/A
- GAIN $3.93
- P/E Ratio
- BCAX N/A
- GAIN $7.91
- Revenue Growth
- BCAX N/A
- GAIN 7.28
- 52 Week Low
- BCAX $7.80
- GAIN $11.42
- 52 Week High
- BCAX $28.09
- GAIN $15.34
- Technical
- Relative Strength Index (RSI)
- BCAX N/A
- GAIN 45.40
- Support Level
- BCAX N/A
- GAIN $14.01
- Resistance Level
- BCAX N/A
- GAIN $14.50
- Average True Range (ATR)
- BCAX 0.00
- GAIN 0.29
- MACD
- BCAX 0.00
- GAIN -0.07
- Stochastic Oscillator
- BCAX 0.00
- GAIN 12.41
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
About GAIN Gladstone Investment Corporation Business Development Company
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to achieve and grow current income by investing in debt securities of established businesses; provide the stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.